206 related articles for article (PubMed ID: 33142932)
1. Identifying Cancer-Relevant Mutations in the DLC START Domain Using Evolutionary and Structure-Function Analyses.
Holub AS; Bouley RA; Petreaca RC; Husbands AY
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142932
[TBL] [Abstract][Full Text] [Related]
2. DLC-1:a Rho GTPase-activating protein and tumour suppressor.
Durkin ME; Yuan BZ; Zhou X; Zimonjic DB; Lowy DR; Thorgeirsson SS; Popescu NC
J Cell Mol Med; 2007; 11(5):1185-207. PubMed ID: 17979893
[TBL] [Abstract][Full Text] [Related]
3. Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger.
Jaiswal M; Dvorsky R; Amin E; Risse SL; Fansa EK; Zhang SC; Taha MS; Gauhar AR; Nakhaei-Rad S; Kordes C; Koessmeier KT; Cirstea IC; Olayioye MA; Häussinger D; Ahmadian MR
J Biol Chem; 2014 Mar; 289(10):6839-6849. PubMed ID: 24443565
[TBL] [Abstract][Full Text] [Related]
4. The Role of Tumor Suppressor DLC-1: Far From Clear.
Liu X; Pan YJ; Zheng JN; Pei DS
Anticancer Agents Med Chem; 2017; 17(7):896-901. PubMed ID: 27604574
[TBL] [Abstract][Full Text] [Related]
5. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver.
Liao YC; Lo SH
Int J Biochem Cell Biol; 2008; 40(5):843-7. PubMed ID: 17521951
[TBL] [Abstract][Full Text] [Related]
6. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1.
Sanchez-Solana B; Wang D; Qian X; Velayoudame P; Simanshu DK; Acharya JK; Lowy DR
Mol Cancer; 2021 Nov; 20(1):141. PubMed ID: 34727930
[TBL] [Abstract][Full Text] [Related]
7. Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration.
Kim TY; Healy KD; Der CJ; Sciaky N; Bang YJ; Juliano RL
J Biol Chem; 2008 Nov; 283(47):32762-70. PubMed ID: 18786931
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function.
Liao YC; Shih YP; Lo SH
Cancer Res; 2008 Oct; 68(19):7718-22. PubMed ID: 18829524
[TBL] [Abstract][Full Text] [Related]
9. DLC-1 tumor suppressor regulates CD105 expression on human non-small cell lung carcinoma cells through inhibiting TGF-β1 signaling.
Zhang K; Na T; Ge F; Yuan BZ
Exp Cell Res; 2020 Jan; 386(2):111732. PubMed ID: 31770531
[TBL] [Abstract][Full Text] [Related]
10. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma.
Ching YP; Wong CM; Chan SF; Leung TH; Ng DC; Jin DY; Ng IO
J Biol Chem; 2003 Mar; 278(12):10824-30. PubMed ID: 12531887
[TBL] [Abstract][Full Text] [Related]
11. The DLC-1 tumor suppressor is involved in regulating immunomodulation of human mesenchymal stromal /stem cells through interacting with the Notch1 protein.
Na T; Zhang K; Yuan BZ
BMC Cancer; 2020 Nov; 20(1):1064. PubMed ID: 33148199
[TBL] [Abstract][Full Text] [Related]
12. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth.
Durkin ME; Ullmannova V; Guan M; Popescu NC
Oncogene; 2007 Jul; 26(31):4580-9. PubMed ID: 17297465
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma.
Wong CM; Lee JM; Ching YP; Jin DY; Ng IO
Cancer Res; 2003 Nov; 63(22):7646-51. PubMed ID: 14633684
[TBL] [Abstract][Full Text] [Related]
14. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.
Healy KD; Hodgson L; Kim TY; Shutes A; Maddileti S; Juliano RL; Hahn KM; Harden TK; Bang YJ; Der CJ
Mol Carcinog; 2008 May; 47(5):326-37. PubMed ID: 17932950
[TBL] [Abstract][Full Text] [Related]
15. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors.
Ullmannova V; Popescu NC
Int J Oncol; 2006 Nov; 29(5):1127-32. PubMed ID: 17016643
[TBL] [Abstract][Full Text] [Related]
16. Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma.
Wolosz D; Walczak A; Szparecki G; Dwojak M; Winiarska M; Wolinska E; Gornicka B
Eur J Histochem; 2019 Feb; 63(1):. PubMed ID: 30827083
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of the Drosophila RhoGAP Cv-c protein and its equivalence to the human DLC3 and DLC1 proteins.
Sotillos S; Aguilar-Aragon M; Hombría JC
Sci Rep; 2018 Mar; 8(1):4601. PubMed ID: 29545526
[TBL] [Abstract][Full Text] [Related]
18. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma.
Kim TY; Lee JW; Kim HP; Jong HS; Kim TY; Jung M; Bang YJ
Biochem Biophys Res Commun; 2007 Mar; 355(1):72-7. PubMed ID: 17292327
[TBL] [Abstract][Full Text] [Related]
19. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development.
Durkin ME; Avner MR; Huh CG; Yuan BZ; Thorgeirsson SS; Popescu NC
FEBS Lett; 2005 Feb; 579(5):1191-6. PubMed ID: 15710412
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B core protein promotes liver cancer metastasis through miR-382-5p/DLC-1 axis.
Du J; Bai F; Zhao P; Li X; Li X; Gao L; Ma C; Liang X
Biochim Biophys Acta Mol Cell Res; 2018 Jan; 1865(1):1-11. PubMed ID: 28982593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
